Abstract
Background: Obesity is a major driver of type 2 diabetes. Weight loss improves glycemia but is seldom sustained. This is partly due to a weight loss-associated decrease in energy expenditure (EE). Current weight loss medications do not target EE. Intravenous glucagon acutely increases EE and reduces food intake (FI) in humans, but hyperglycemia precludes its use for weight loss. We have previously shown that intranasal glucagon (ING) paradoxically attenuates hyperglycemia. Here, we report the acute effects of ING on EE and FI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
